Drug or intervention
Rituximab Clinical Trials
Studies that test Rituximab, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 469Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic…
- Trial name
- NCT04840602
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 146 sites in United States
- Volunteers
- 92 people
- Sponsor
- National Cancer Institute (NCI)
Follicular Lymphoma
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy.
- Trial name
- NCT07634471
- Testing
- MK-1045, Rituximab, Rituximab biosimilar
- Where
- 35 sites in United States, Argentina and 11 more
- Volunteers
- 960 people
- Sponsor
- Merck Sharp & Dohme LLC
Nephrotic Syndrome, Proteinuria
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
Background: Membranous nephropathy is associated with damage to the walls of the glomeruli, the small blood vessels in the kidneys that filter waste products from the blood.
- Conditions
- Nephrotic Syndrome, Proteinuria, Autoimmune Disease, Glomerular Disease
- Trial name
- NCT00977977
- Testing
- Rituximab Infusion, Oral Cyclosporine
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody.
- Trial name
- NCT06337318
- Testing
- Biospecimen Collection, Computed Tomography, Mosunetuzumab
- Where
- 288 sites in United States
- Volunteers
- 600 people
- Sponsor
- National Cancer Institute (NCI)
Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Background: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cured have a poor prognosis.
- Conditions
- Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, DLBCL, NHL
- Trial name
- NCT04002947
- Testing
- DA-EPOCH, Rituximab, CHOP
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- National Cancer Institute (NCI)
KSHV Inflammatory Cytokine Syndrome (KICS), KSHV
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
Background: KSHV inflammatory cytokine syndrome (KICS) is a newly recognized disease caused by Kaposi sarcoma-associated herpesvirus (KSHV). This virus can cause cancer. People with KICS can have severe symptoms.
- Conditions
- KSHV Inflammatory Cytokine Syndrome (KICS), KSHV, HHV-8
- Trial name
- NCT01419561
- Testing
- Zidovudine, Liposomal Doxorubicin, Valganiclovir
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed/Refractory Non-Hodgkin Lymphoma
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6…
- Trial name
- NCT06090539
- Testing
- BMS-986458, Rituximab, Glofitamab/Obinutuzumab
- Where
- 76 sites in United States, Chile and 13 more
- Volunteers
- 460 people
- Sponsor
- Bristol-Myers Squibb
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma…
- Trial name
- NCT06943872
- Testing
- Sonrotoclax, Obinutuzumab, Rituximab
- Where
- 195 sites in United States, Argentina and 19 more
- Volunteers
- 630 people
- Sponsor
- BeOne Medicines
Lymphoma, Primary Central Nervous System Lymphoma
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
This research study is studying if the investigational drug, Pembrolizumab, in combination with chemotherapy helps primary central nervous system lymphoma with acceptable side effects.
- Trial name
- NCT06475235
- Testing
- Pembrolizumab, Methotrexate, Temozolomide
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
This phase I/II trial tests the safety, side effects, best dose and effectiveness of golcadomide in combination with rituximab in treating patients with mantle cell lymphoma that has come back after a period of improvement…
- Trial name
- NCT07578077
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- City of Hope Medical Center
Completed, with results posted
All 569Myositis Associated Interstitial Lund Disease (MA-ILD)
Myositis Interstitial Lung Disease Nintedanib Trial
This research study will evaluate safety and how well the study drug, nintedanib improve symptoms in participants with myositis associated interstitial lung disease (MA-ILD).
- Trial name
- MINT (NCT05799755)
- Testing
- Nintedanib, Standard of Care
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- Rohit Aggarwal, MD
Chronic Lymphocytic Leukemia
Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia
The purpose of this study is to determine the efficacy of bendamustine and rituximab (BR) followed by venetoclax for 12 months. The total time on therapy is 15 months.
- Trial name
- NCT03609593
- Testing
- Bendamustine, Venetoclax, Rituximab
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Nicole Lamanna
Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
This phase II trial studies whether rituximab and hyaluronidase human (Rituxan Hycela) can prevent immune related adverse events in participants with stage III-IV melanoma that cannot be removed by surgery who are undergoing…
- Conditions
- Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Stage III Melanoma, Stage IIIA Skin Melanoma
- Trial name
- NCT03719131
- Testing
- Nivolumab, Rituximab and Hyaluronidase Human, Ipilimumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Emory University
Kidney Transplant, Kidney Transplant Recipient
Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies
The purpose of this study is to determine whether treatment with rituximab (anti-CD20, Rituxan®, MabThera®) in individuals who develop new anti-HLA antibodies after renal (kidney) transplant will promote longer-term survival of…
- Conditions
- Kidney Transplant, Kidney Transplant Recipient, Graft Function/Survival, de Novo HLA Antibodies Development
- Trial name
- NCT00307125
- Testing
- Rituximab plus immunosuppression
- Where
- 17 sites in United States
- Volunteers
- 757 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Vasculitis
Acquired Immunodeficiency in ANCA Associated Vasculitis
This study will address the following hypothesis: Rituximab therapy leads to an acquired immune deficiency, as demonstrated by impaired vaccine responses, in AAV patients. Aims: 1.
- Trial name
- ACQUIVAS (NCT03514979)
- Testing
- Pneumococcal Polysaccharide Conjugate vaccination and Pneumococcal Polysaccharide Vaccination
- Where
- United Kingdom
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust